Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC) | 2024 | Lung Cancer (Amsterdam, Netherlands) |
Correlation between ALK+ non-small cell lung cancer targeted therapy and thrombosis: a systematic review and network meta-analysis | 2024 | Bmj Open |
Efficacy of ALK inhibitors in Asian patients with ALK inhibitor-naive advanced ALK-positive non-small cell lung cancer: a systematic review and network meta-analysis | 2024 | Translational Lung Cancer Research |
Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence | 2024 | Lung Cancer (Amsterdam, Netherlands) |
Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis | 2024 | Bmc Cancer |
Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments | 2023 | Frontiers In Oncology |
Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis | 2023 | Exploration Of Targeted Anti-Tumor Therapy |
Adverse Side Effects of Crizotinib in the Treatment of Anaplastic Lymphoma Kinase-Mutated Non-small Cell Lung Cancer: A Systematic Review | 2023 | Cureus |
Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis | 2023 | Lung Cancer (Amsterdam, Netherlands) |
Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review | 2023 | Frontiers In Pharmacology |
A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer | 2023 | Cancer Medicine |
Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden | 2023 | Applied Health Economics And Health Policy |
Efficacy and safety of anaplastic lymphoma kinase inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis | 2023 | Thoracic Cancer |
Comparative Efficacy of ALK Inhibitors for Treatment-Naive ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis | 2023 | International Journal Of Molecular Sciences |
Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis | 2023 | Cancer |
Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis | 2022 | Frontiers In Oncology |
ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis | 2022 | Bmj Open |
Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer | 2022 | Frontiers In Oncology |
Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis | 2022 | Frontiers In Pharmacology |
A Systematic Review of Companion Diagnostic Tests by Immunohistochemistry for the Screening of Alectinib-Treated Patients in ALK-Positive Non-Small Cell Lung Cancer | 2022 | Diagnostics (Basel, Switzerland) |
Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis | 2022 | Investigational New Drugs |
Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer | 2022 | The Cochrane Database Of Systematic Reviews |
Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis | 2021 | Frontiers In Oncology |
First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis | 2021 | Journal Of Clinical Medicine |
ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis | 2021 | Lung Cancer (Amsterdam, Netherlands) |
Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis | 2021 | Cancers |
Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis | 2021 | Oncology And Therapy |
Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naive ALK-Positive Lung Cancer | 2021 | Cancers |
Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis | 2020 | Targeted Oncology |
Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer | 2020 | Journal Of Comparative Effectiveness Research |
Efficacy and safety of ceritinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer: A systematic review and meta-analysis | 2020 | Journal Of Clinical Pharmacy And Therapeutics |
Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer With or Without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis | 2020 | Cancers |
ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis | 2020 | Plos One |